Business Description
Defence Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA24463V1013
Compare
Compare
Traded in other countries / regions
DTC.CanadaDTC.GermanyDTCFF.USA IPO Date
2021-05-14Description
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.23 | |||||
| Equity-to-Asset | -3.43 | |||||
| Debt-to-Equity | -0.66 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.34 | |||||
| 9-Day RSI | 48.52 | |||||
| 14-Day RSI | 43.49 | |||||
| 6-1 Month Momentum % | -51.66 | |||||
| 12-1 Month Momentum % | -63.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.18 | |||||
| Quick Ratio | 0.18 | |||||
| Cash Ratio | 0.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -7.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -810.52 | |||||
| ROIC % | -2440.38 | |||||
| ROC (Joel Greenblatt) % | -17639.54 | |||||
| ROCE % | -3054.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -5.48 | |||||
| EV-to-EBITDA | -5.49 | |||||
| EV-to-FCF | -14.67 | |||||
| Earnings Yield (Greenblatt) % | -18.25 | |||||
| FCF Yield % | -7.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:DTCFF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Defence Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.201 | ||
| Beta | 2.78 | ||
| Volatility % | 37.76 | ||
| 14-Day RSI | 43.49 | ||
| 14-Day ATR ($) | 0.028577 | ||
| 20-Day SMA ($) | 0.968176 | ||
| 12-1 Month Momentum % | -63.38 | ||
| 52-Week Range ($) | 0.85608 - 3.19 | ||
| Shares Outstanding (Mil) | 45.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Defence Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Defence Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Defence Therapeutics Inc Frequently Asked Questions
What is Defence Therapeutics Inc(DTCFF)'s stock price today?
The current price of DTCFF is $0.98. The 52 week high of DTCFF is $3.19 and 52 week low is $0.86.
When is next earnings date of Defence Therapeutics Inc(DTCFF)?
The next earnings date of Defence Therapeutics Inc(DTCFF) is .
Does Defence Therapeutics Inc(DTCFF) pay dividends? If so, how much?
Defence Therapeutics Inc(DTCFF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers